關鍵數據
1.610今開
1.640最高
36.00K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.35%換手率
1.560昨收
1.450最低
26.94K成交額
虧損本益比靜
-0.87市淨率
0.00%股息率 TTM
-84.91%ROA
5.96052週最高
2.63量比
-22.58M淨利潤
10.43M總股本
-2.9077每股盈餘TTM
0.66Beta
-1205.58%ROE
2.22052週最低
12.18%振幅
33.53%毛利率
16.17M總市值
-6.41回報/風險
4.07%風險率
操作建議
Pluri Inc當前公司基本面數據相對謹慎,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名203/385位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為12.00。中期看,股價處於下降通道。近一個月,市場表現非常差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Pluri Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
25
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Pluri Inc簡介
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
公司代碼PLUR
公司Pluri Inc
CEOYanay (Yaky)
網址https://pluri-biotech.com/
公司股東
常見問題
Pluri Inc(PLUR)的當前股價是多少?
Pluri Inc(PLUR)的當前股價是 1.56。
Pluri Inc(PLUR)股票的每股收益(EPS TTM)是多少
Pluri Inc(PLUR)股票的每股收益(EPS TTM)是-3.56。